These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum].
    Author: Ishii N, Ishida Y, Okano Y, Ozaki M, Gidoh M, Kumano K, Goto M, Nogami R, Hatano K, Yamada A, Yotsu RR.
    Journal: Nihon Hansenbyo Gakkai Zasshi; 2011 Sep; 80(3):275-85. PubMed ID: 21941834.
    Abstract:
    Treatment of erythema nodosum leprosum (ENL, type 2 reaction) using thalidomide provides effective alternative choice to steroid therapy. Yet, the Japanese National Health Insurance approves thalidomide prescription only for the treatment of multiple myeloma under the Thalidomide Education and Risk Management System (TERMS). Benefit of thalidomide therapy for patients with ENL is already an established fact based on various reports from other countries, but limited experiences and standards in Japan have hindered application of the medication to our patients. This led us to compose a local guideline. Based on and following the TERMS, we suggest starting thalidomide from 50-100 mg/day and then onwards adjusting the dose according to the symptoms of each patient, not to exceed the maximum recommended dose of 300 mg/day, for the treatment of ENL.
    [Abstract] [Full Text] [Related] [New Search]